bevacizumab,atezolizumab
roche
['avastin', 'tecentriq', 'imbrave-050', 'rova,(-approval),(-microvascular)', '$rhhby']
 $rhhby tecentriq + avastin beat active surveillance in adjuvant liver cancer (hr=0.72, p=0.0120 for relapse-free survival) in imbrave-050. i'm guessing rfs is an approvable endpoint here, but what's the contribution of avastin? #aacr23
Journalist at Evaluate Vantage. Interested in: oncology, immunology. Not interested in: what stock you bought today.